Evidence map›Paper›PMID 38185520›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2023

[Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].

L L An, D F Zhao, R F Hou, H H Guan, H Yan, Y H Lin, C R Tong, T Wu, S Y Liu

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Inotuzumab Ozogamicin in Indian Patients with B-Cell Acute Lymphoblastic Leukemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

L L AnBeijing GoBroad Boren Hospital, Beijing 100070, China.
D F ZhaoBeijing GoBroad Boren Hospital, Beijing 100070, China.
R F HouBeijing GoBroad Boren Hospital, Beijing 100070, China.
H H GuanBeijing GoBroad Boren Hospital, Beijing 100070, China.
H YanBeijing GoBroad Boren Hospital, Beijing 100070, China.
Y H LinBeijing GoBroad Boren Hospital, Beijing 100070, China.
C R TongBeijing GoBroad Boren Hospital, Beijing 100070, China.
T WuBeijing GoBroad Boren Hospital, Beijing 100070, China.
S Y LiuBeijing GoBroad Boren Hospital, Beijing 100070, China.
Beijing United Family Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chemical and Drug Induced Liver InjuryPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAdaptor Proteins, Signal TransducingAdolescentAdultAntibodies, MonoclonalAntigens, CD19ChildHumansInotuzumab OzogamicinAdaptor Proteins, Signal TransducingAntibodies, MonoclonalAntigens, CD19Inotuzumab OzogamicinReceptors, Chimeric AntigenCD22Inotuzumab ozogamicinLeukemia, B-cell, acuteRelapsed/refractory

Identifiers

PMID38185520
PMCPMC10753260
OpenAlexW4390689824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.